BTIG Maintains Buy on Haemonetics, Raises Price Target to $96

Haemonetics Corporation

Haemonetics Corporation

HAE

0.00

BTIG analyst Marie Thibault maintains Haemonetics (NYSE: HAE) with a Buy and raises the price target from $84 to $96.